Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room (ReCovER)

• ClinicalTrials.gov Identifier: NCT04351854
• Recruitment Status: Recruiting
• First Posted: April 17, 2020
• Last Update Posted: December 10, 2020
• Sponsor: University of Cologne
• Information provided by (Responsible Party): Volker Burst, University of Cologne

Study Description

Brief Summary:

Patients with COVID-19 usually present in the ED and receive their initial medical check-up here. We will try to gather information of comorbidities and other conditions at the time of presentation of COVID-19 patients to the ED. The course of the disease prior to admission as well as the momentary health status at presentation to the ED are of interest because they influence risk stratification and decision-making of treating physicians. The ratio of patients with mild or moderate to severe symptoms will help to calculate the need for hospital beds including beds on Intensive Care Units (ICU) and Intermediate Care Units (IMC), as well as the need for other hospital resources.

Condition or disease	Intervention/treatment
Corona Virus Infection; SARS-CoV 2	Other: Retrospective data collection

Detailed Description:

Patients with COVID-19 usually present in the ED and receive their initial medical check-up here. It is the ED where crucial diagnostic and therapeutic steps are taken and where the decision for admission or discharge is made. As of now, the effectiveness and value of these initial measures and decisions are unclear. With still raising numbers of infections despite regulatory constraints in place, there is an urgent need to develop valid decision trees on how to treat patients suspected with COVID-19 in the ED.

Apart from the already described risk factors little is known about if and to which degree an infection with COVID-19 itself predisposes to other acute conditions (e.g. myocarditis, myocardial infarction or stroke). We will try to gather information of comorbidities and other conditions at the time of presentation of COVID-19 patients to the ED.

Not all patients seek medical consultation at the very beginning of symptoms. The course of the disease prior to admission as well as the momentary health status at presentation to the ED are of interest because they influence risk stratification and decision-making of treating physicians. For example: an immunocompromised patient who presents with mild symptoms at a very early stage of COVID-19 would probably be deemed more at risk than the same patient who reports mild symptoms without progression for a duration of several weeks.

The ratio of patients with mild or moderate to severe symptoms will help to calculate the need for hospital beds including beds on Intensive Care Units (ICU) and Intermediate Care Units (IMC), as well as the need for other hospital resources. It will also help to identify the need for capacities in ambulatory care. COVID-19 Patients with mild or moderate symptoms can remain in quarantine at home. This would not only disburden hospitals but would also lower the risk for previously uninfected patients otherwise having to share rooms and wards with them.

Confirming the diagnosis There is uncertainty with regard to the best initial diagnostic in COVID-19 patients. Diagnostic tool of choice is a low-dose CT-scan of the thorax, which will detect typical radiologic signs of COVID-19 (ground-glass-opacities, bilateral consolidations and "crazy paving") with a high sensitivity, and in some cases even before onset of clinical symptoms. However, these features are also seen in other viral pneumonias and specificity reaches only 25%. Moreover, a CT-scan might not be available 24/7 in all hospitals, is time-consuming and exposes radiologic personnel to the risk of infection. Additionally, as is described later, many patients present with severe hypoxemia, a situation in which they might not be able to lie in a supine position in the CT-scanner. The role of lung ultrasound (LUS) in detection of COVID-19 has not been examined properly so far.

Testing for COVID-19 usually is done using an oral swab (or expectorated sputum) and real-time PCR (RT-PCR) after a clinical suspicion based on different parameters and/or after visits of the patient to regions with high prevalence of SARS-CoV-2. The sensitivity of this method has not been systematically evaluated, however, false-positive, as well as false-negative results have been reported. Moreover, there are sometimes contradictory results of RT-PCR and CT-scan. The registry will be used to collect and compare diagnostic data from radiological exams as well as RT-PCR-testing.

Many COVID-19 patients present with shortness of breath and hypoxemia. Physicians have used different therapeutic approaches including high-flow oxygen (HFNC), non-invasive ventilation or intubation and mechanical ventilation. While a trial with non-invasive methods is deemed safe and adequate by most experts, others have raised concerns and advocate early intubation and invasive ventilation in COVID-19. Participants of the registry will be asked to state the method of oxygenation/ventilatory support that was initiated in the ED.

Admission vs. discharge As has already been laid out, patients with COVID-19 exhibit symptoms of different severity. It is neither possible nor would it be reasonable to hospitalize every patient in which the condition is suspected or confirmed. Unfortunately, there are no diagnostic markers or laboratory cut-offs that help decide if a COVID-19 patient who presents to the ED has to be hospitalized or can be safely managed in ambulatory care. Our goal is to gather information of outcomes in both hospitalized and discharged patients and to compare this data with epidemiological, clinical, laboratory and radiologic data from the date of their visit to the ED.

The ED is the first contact to a hospital. Diagnostic and therapeutic measures from patients who are hospitalized due to the severity of their disease will be analyzed as well as complications or death during hospitalization. The duration of hospitalization will be analyzed and compared to the initial clinical picture.

Study Design

• Study Type: Observational
• Estimated Enrollment: 500 participants
• Observational Model: Case-Control
• Time Perspective: Retrospective
• Official Title: Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room
• Actual Study Start Date: April 20, 2020
• Estimated Primary Completion Date: December 31, 2025
• Estimated Study Completion Date: August 31, 2026

Groups and Cohorts

Group/Cohort	Intervention/treatment
Patients with SARS-CoV-2-infection; Patients with clinical suspicion or evidence of SARS-CoV-2-infection on presentation in the ED	Other: Retrospective data collection; Retrospective data collection to identify predicting factors in the clinical picture of COVID-19 patients presenting to the ED.
Control group; Particularly, controls will be identified retrospectively at the same hospitals based on matching of demographics, underlying diseases and duration of hospital stay (i.e. one control per case, both in the same hospital). Moreover, the mere suspicion of SARS-CoV-2-infection on admission in the ED is sufficient for enrolment. A considerable portion of these patients are actually not infected and serve as internal control.	Other: Retrospective data collection; Retrospective data collection to identify predicting factors in the clinical picture of COVID-19 patients presenting to the ED.

Outcome Measures

Primary Outcome Measures :

1. Identification of risk factors present at the earliest stage of hospital care (i.e. in the ED) that warrant hospital admission. [ Time Frame: 6 months ]
   Identification of risk factors present at the earliest stage of hospital care (i.e. in the ED) that warrant hospital admission.

Secondary Outcome Measures :

1. Determination of the course of the disease (days since onset of symptoms, nature of symptoms, e.g. fever, chills, headache) and the state at which patients present to the ED [ Time Frame: 6 months ]
   Determination of the course of the disease (days since onset of symptoms, nature of symptoms, e.g. fever, chills, headache) and the state at which patients present to the ED
2. Identification of the ratio of patients with mild or moderate to severe disease [ Time Frame: 6 months ]
   Identification of the ratio of patients with mild or moderate to severe disease

Eligibility Criteria

• Ages Eligible for Study: Child, Adult, Older Adult
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Probability Sample

Study Population

Patients with clinical suspicion or evidence of SARS-CoV-2-infection on presentation in the ED and matching controls, based on demographics, underlying diseases and duration of hospital stay (i.e. one control per case, both in the same hospital).

Criteria

Inclusion Criteria:

• Clinical suspicion or evidence of SARS-CoV-2-infection on presentation in the ED

Exclusion Criteria:

• None

Contacts and Locations

Contacts

Contact: Volker Burst, MD; +4922147897222; volker.burst@uk-koeln.de

Contact: Victor Suarez, MD; +4922147897222; victor.suarez@uk-koeln.de

Locations

Germany

University Hospital of Cologne; Recruiting

Cologne, Germany, 50937

Contact: Volker Burst, MD +49(0)221 478 86285 volker.burst@uk-koeln.de

Contact: Victor Suarez, MD victor.suarez@uk-koeln.de

Sponsors and Collaborators

University of Cologne

More Information

• Responsible Party: Volker Burst, PD Dr. med., University of Cologne
• ClinicalTrials.gov Identifier: NCT04351854
• Other Study ID Numbers: ReCovER
• First Posted: April 17, 2020
• Last Update Posted: December 10, 2020
• Last Verified: December 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Coronavirus Infections; Severe Acute Respiratory Syndrome; Emergencies; Disease Attributes; Pathologic Processes; Virus Diseases; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Respiratory Tract Infections; Respiratory Tract Diseases